No Data
RxSight Cut to Hold at Stifel on Competition Concerns
UBS's Global Equity Focus List: Stocks Within Health Technology
UBS Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $105.57
This Is Why You Should Turn Defensive, Underweight Cyclicals – UBS
Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk
Alcon Top Pick for 2025 at Needham, Added to Conviction List
loading...